ARD103
Drug Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | ARD103 |
| Trade Name | |
| Synonyms | ARD 103|ARD-103 |
| Drug Descriptions |
ARD103 are T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CLEC12A (CLL1) that contains CD28 transmembrane and co-stimulatory domains and a CD3zeta activation domain, which may inhibit growth of CLL1-expressing tumor cells (JCO Global Oncol 2023 9: Supplement_1, 119). |
| DrugClasses | |
| CAS Registry Number | NA |
| NCIT ID | NA |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| ARD103 | ARD103 | 0 | 1 |
CKB BOOST